Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Whitehawk Therapeutics, Inc.ARPO · Entity 6074 | See Remarks | March 16, 2020 | March 18, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Whitehawk Therapeutics, Inc.
Report date March 16, 2020 · Filed March 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.52 · Expires 2030-03-16 | Direct | 129,000 |
Reported balance
After 2020-03-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-03-16 · Grant · Acquired 129,000 · Balance 129,000 F1: Options exercisable as to 1/4th on March 16, 2021 and an additional 1/48th monthly thereafter until March 16, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Options exercisable as to 1/4th on March 16, 2021 and an additional 1/48th monthly thereafter until March 16, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 16, 2020 Filed Mar 18, 2020 22:10 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 129,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0000899243-20-008922 · doc4.xml · derivative · entry 1 PETERS KEVIN G. · CIK 0001700663 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,000 Underlying: Common Stock · 129,000 shares Expires 2030-03-16 F1 · derivative.exercise_date: Options exercisable as to 1/4th on March 16, 2021 and an additional 1/48th monthly thereafter until March 16, 2024. Read SEC document |
| May 14, 2019 Filed May 16, 2019 21:12 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 266,550 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0000899243-19-013764 · doc4.xml · derivative · entry 2 PETERS KEVIN G. · CIK 0001700663 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,550 Underlying: Common Stock · 266,550 shares Expires 2029-05-14 F2 · derivative.exercise_date: 50% of the shares shall vest on June 30, 2020 and the remaining 50% shall vest on June 30, 2021. Read SEC document |
| May 14, 2019 Filed May 16, 2019 21:12 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 63,250 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0000899243-19-013764 · doc4.xml · derivative · entry 1 PETERS KEVIN G. · CIK 0001700663 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,250 Underlying: Common Stock · 63,250 shares Expires 2029-05-14 F1 · derivative.exercise_date: Options exercisable as to 1/4th on the first anniversary of the grant date and an additional 1/48th monthly thereafter until the fourth anniversary of the grant date. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 21:52 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0000899243-19-004273 · doc4.xml · derivative · entry 1 PETERS KEVIN G. · CIK 0001700663 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2029-02-15 F1 · derivative.exercise_date: Options exercisable as to 1/4th on the first anniversary of the grant date and an additional 1/48th monthly thereafter until the fourth anniversary of the grant date. Read SEC document |
| April 23, 2018 Filed Apr 26, 2018 00:26 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0000899243-18-010750 · doc4.xml · derivative · entry 1 PETERS KEVIN G. · CIK 0001700663 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-04-23 F1 · derivative.exercise_date: Options exercisable as to 1/4th on the first anniversary of the grant date and an additional 1/48th monthly thereafter until the fourth anniversary of the grant date. Read SEC document |
| March 15, 2017 Filed Mar 18, 2017 00:41 UTC | Whitehawk Therapeutics, Inc. NONE · Entity 6074 | PurchaseCommon Stock | 3,642 | $5.00 | $18,210.00 |
DisclosureSEC source: 0000899243-17-008160 · doc4.xml · nonDerivative · entry 1 PETERS KEVIN G. · CIK 0001700663 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,536 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.